寨卡病毒疫苗的开发研究综述。
A review on Zika vaccine development.
机构信息
The Key Laboratory of Microbiology and Parasitology of Anhui Province, the Key Laboratory of Zoon-oses of High Institutions in Anhui, Department of Pathogen Biology, School of Basic Medical Sciences, Anhui Medical University, Hefei 230032, China.
Institute of Agro-products Processing, Anhui Academy of Agricultural Sciences, Hefei 230031, Anhui, China.
出版信息
Pathog Dis. 2024 Feb 7;82. doi: 10.1093/femspd/ftad036.
Zika virus (ZIKV), which belongs to the Flavivirus family, is mainly transmitted via the bite of Aedes mosquitoes. In newborns, ZIKV infection can cause severe symptoms such as microcephaly, while in adults, it can lead to Guillain‒Barré syndrome (GBS). Due to the lack of specific therapeutic methods against ZIKV, the development of a safe and effective vaccine is extremely important. Several potential ZIKV vaccines, such as live attenuated, inactivated, nucleic acid, viral vector, and recombinant subunit vaccines, have demonstrated promising outcomes in clinical trials involving human participants. Therefore, in this review, the recent developmental progress, advantages and disadvantages of these five vaccine types are examined, and practical recommendations for future development are provided.
Zika 病毒（ZIKV）属于黄病毒科，主要通过伊蚊叮咬传播。新生婴儿感染 ZIKV 可引发小头症等严重症状，而成人感染则可能导致格林-巴利综合征（GBS）。由于缺乏针对 ZIKV 的特效治疗方法，因此开发安全有效的疫苗极为重要。几种有潜力的 ZIKV 疫苗，如减毒活疫苗、灭活疫苗、核酸疫苗、病毒载体疫苗和重组亚单位疫苗，在涉及人类参与者的临床试验中已显示出良好的效果。因此，本综述对这五种疫苗类型的最新研发进展、优缺点进行了考察，并为未来的发展提供了实用建议。
Zotero 插件